-+ 0.00%
-+ 0.00%
-+ 0.00%

NERVGEN RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR NVG-291 IN CHRONIC SPINAL CORD INJURY

Reuters·11/12/2026 12:15:00

Please log in to view news